Treatment of Therapy-Resistant Hyperlipidaemia after Heart Transplant with PCSK9-Inhibitors
Hyperlipidemia is a major factor in the development of graft vasculopathy (GVP) after heart transplant. The incidence of hyperlipidaemia in heart transplant (HTX) patients under immunosuppressive therapy is 74% in the first year, and 91% in the first five years. Lipid-lowering therapy with statins presents a great challenge due to interactions and adverse effects. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have already proven very effective in high-risk cardiovascular patients.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: K. Uyanik-Uenal, M. Stoegerer-Lanzenberger, K. Auersperg, A. Aliabadi-Zuckermann, G. Laufer, A. Zuckermann Tags: 510 Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Heart | Heart Transplant | Lung Transplant | Statin Therapy | Transplant Surgery | Transplants